arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

DiaMedica Therapeutics Inc.

DMAC Health Care Biotechnology: Pharmaceutical Preparations
$8.72
▲ +0.3% Today
as of Oct 23, 16:48 ET
Last 30 days +33.13% Sep 14 → Oct 23
$6.35 $6.99 $7.63 $8.26 $8.90 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$8.55
High
$8.75
Low
$8.29
Volume
$110,025
Avg Vol
$245,968
Mkt Cap
$450M
P/E (TTM)
—
Beta
—
52w High
$10.42
52w Low
$5.25
Div Yield
—
Shares Out
$54M

Recent Press Releases & News last 60 days · 6 items

Oct 22 · 14:11 MT Newswires
DiaMedica Therapeutics Reaches Patient Enrollment Milestone for Phase 2/3 Trial of DM199 in Acute Ischemic Stroke
Oct 22 · 12:00 PR Business Wire
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
Oct 19 · 12:00 PR Business Wire
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
▸ Show all 6 press releases & news Free account →

DMAC earnings at a glance

The options market is pricing a move of about ±21.2% after the report, a range of roughly $6.87 to $10.57 from today's $8.72. Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±4.2% on average; after the most recent report on May 6, 2026 it moved +4.3%. That means options currently expect more movement than DMAC has typically delivered. DMAC beat the consensus EPS estimate in 0 of its last 4 reported quarters. Implied volatility is currently 180%. The share price of $8.72 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$5.25
$10
67% of range
Avg surprise (last 4)
-6.3%
Avg reaction (last 2)
+4.2%
100% positive
Latest IV / EM
180%
EM ±21.2% · $8 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.69$-0.43$-0.17$0.09$0.35 Actual $-0.18Est $-0.18Actual $-0.18Est $-0.18Actual $-0.17Est $-0.15Actual $-0.19Est $-0.17 Mar/2025Jun/2025Sep/2025Mar/2026
Revenue vs Net Income Revenue Net income
$-10M$-9M$-8M$-7M$-7M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed May 6, 2026Mar/2026 $-0.19 $-0.17 -11.8% -5.6% +4.3% earnings
Wed Nov 12, 2025Sep/2025 $-0.17 $-0.15 -13.3% — — earnings
Tue Aug 12, 2025Jun/2025 $-0.18 $-0.18 0.0% — — earnings
Tue May 13, 2025Mar/2025 $-0.18 $-0.18 0.0% — +4.1% earnings

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-10M$-10M—$-9M$-8M$-8M—$-7M
Net income$-10M$-10M—$-9M$-8M$-8M—$-6M
EPS (diluted)————————

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$5M$5M$16M$3M$4M$3M$3M$4M
Inventory————————
Total current assets$44M$52M$61M$56M$31M$37M$45M$51M
Total assets$45M$53M$61M$57M$31M$39M$46M$53M
Long-term debt————————
Total liabilities————————
Total equity$38M$47M$56M$52M$27M$34M$41M$48M

Implied volatility — last 90 days

39%207%375%542%710% Jun 08 — IV 236% · EM ±31.2%Jun 09 — IV 228% · EM ±28.6%Jun 10 — IV 612% · EM ±72.2%Jun 15 — IV 454% · EM ±32.9%Jun 17 — IV 710% · EM ±29.7%Jun 22 — IV 207% · EM ±43.3%Jun 23 — IV 160% · EM ±32.6%Jun 24 — IV 224% · EM ±44.8%Jun 25 — IV 415% · EM ±81.3%Jun 29 — IV 207% · EM ±36.7%Jun 30 — IV 144% · EM ±24.9%Jul 01 — IV 121% · EM ±20.2%Jul 06 — IV 180% · EM ±25.0%Jul 07 — IV 223% · EM ±29.4%Jul 08 — IV 206% · EM ±25.8%Jul 09 — IV 143% · EM ±16.9%Jul 14 — IV 233% · EM ±16.8%Jul 16 — IV 185% · EM ±7.7%Jul 20 — IV 60% · EM ±14.3%Jul 21 — IV 102% · EM ±23.7%Jul 22 — IV 63% · EM ±14.4%Jul 23 — IV 111% · EM ±24.9%Jul 24 — IV 106% · EM ±23.4%Jul 28 — IV 44% · EM ±9.0%Jul 30 — IV 169% · EM ±33.0%Aug 03 — IV 149% · EM ±26.5%Aug 04 — IV 40% · EM ±6.9%Aug 06 — IV 144% · EM ±23.3%Aug 07 — IV 232% · EM ±36.3%Aug 10 — IV 136% · EM ±18.8%Aug 13 — IV 414% · EM ±48.9%Aug 14 — IV 108% · EM ±12.0%Aug 17 — IV 235% · EM ±19.6%Aug 19 — IV 249% · EM ±14.7%Aug 20 — IV 643% · EM ±26.8%Aug 25 — IV 92% · EM ±18.9%Aug 28 — IV 245% · EM ±46.9%Sep 01 — IV 198% · EM ±34.1%Sep 02 — IV 173% · EM ±28.9%Sep 03 — IV 203% · EM ±32.8%Sep 04 — IV 431% · EM ±67.4%Sep 07 — IV 487% · EM ±67.4%Sep 08 — IV 249% · EM ±32.9%Sep 09 — IV 248% · EM ±31.1%Sep 14 — IV 302% · EM ±25.2%Sep 16 — IV 498% · EM ±29.4%Sep 17 — IV 542% · EM ±22.6%Sep 21 — IV 69% · EM ±14.5%Sep 22 — IV 90% · EM ±18.3%Sep 23 — IV 83% · EM ±16.5%Sep 25 — IV 99% · EM ±18.9%Sep 28 — IV 156% · EM ±27.6%Sep 29 — IV 163% · EM ±28.0%Sep 30 — IV 166% · EM ±27.8%Oct 01 — IV 167% · EM ±26.9%Oct 02 — IV 171% · EM ±26.7%Oct 06 — IV 154% · EM ±20.3%Oct 07 — IV 155% · EM ±19.4%Oct 08 — IV 180% · EM ±21.2%

Sector peers

EVMN
Evommune, Inc.
$472M $5.10-1.4%
ARVN
Arvinas, Inc.
$487M $7.30-3.4%
ACRS
Aclaris Therapeutics, Inc.
$500M $3.75-1.6%
CBIO
Crescent Biopharma, Inc.
$501M $12.82-2.7%
TTRX
Turn Therapeutics Inc.
$396M $10.28+1.3%
PBYI
Puma Biotechnology Inc
$506M $11.02+1.1%

DMAC earnings FAQ

What is DMAC's expected move for earnings?

Options currently price a move of about ±21.2%, or $1.85 per share either way from $8.72.

How does DMAC stock usually react to earnings?

Across the last 2 reports the average next-day move was ±4.2%, up 2 times and down 0 times.

What is DMAC's implied volatility?

DMAC's at-the-money implied volatility is about 180% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in